Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivo

Drug Metabolism and Disposition

Volumn 28, Issue 2, 2000, Pages 131-138

  Arora, Vikram ^a   Iversen, Patrick L ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLINE; CYTOCHROME P450 ISOENZYME; DNA; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN P21; PROTEIN P53; SODIUM CHLORIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; DRUG METABOLISM; ENZYME ACTIVITY; FLOW CYTOMETRY; IN VIVO STUDY; LIVER REGENERATION; LIVER WEIGHT; MALE; NONHUMAN; OXIDATIVE STRESS; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RAT; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTOCHROME P-450 ENZYME SYSTEM; DNA; FLOW CYTOMETRY; GENES, P53; HEPATECTOMY; LIVER; LIVER REGENERATION; MALE; MICROSOMES, LIVER; MITOTIC INDEX; NADH, NADPH OXIDOREDUCTASES; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; THIOBARBITURIC ACID REACTIVE SUBSTANCES; WEIGHT GAIN;

ANIMALIA; MAMMALIA;

EID: 0033967806     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Agrawal S and Zhang R (1997) Pharmacokinetics of phosphorothioate oligonucleotides and their novel analogs, in Antisense Oligodeoxynucleotides and Antisense RNA (Weiss B ed) pp 57-78. CRC Press, Boca Raton, FL.
2. Allen WM (1950) A simple method for analyzing complicated absorption curves used in the colorimetric determination of urinary steroids. J Clin Endocrinol 10:71-83.
3. Arora V, Iversen PL, and Ebadi M (1998) Manipulation of metallothionein expression in the regenerating rat liver using antisense oligonucleotides. Biochem Biophys Res Commun 246: 711-718.
4. Assy N, Gong Y, Zhang M, Peltigrew NM, Pashniak D and Minuk GY (1998) Use of proliferating cell nuclear antigen as a marker of liver regeneration after partial hepatectomy in rats. J Lab Clin Med 131:251-256.
5. Bucher NLR (1995) Liver regeneration-then and now, in Liver Regeneration and Carcinogenesis-Molecular and Cellular Mechanisms (Jirtle RL ed) pp 1-26, Academic Press, San Diego.
6. Burke M, Thompson S, Elcombe C, Halpert J, Haaparanta T and Mayer R (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochrome P450s. Biochem Pharmacol 34:3337-3345.
7. Chen IT, Smith ML, O'Connor PM and Fornace AJ Jr (1995) Direct interaction of Gadd45 and p21waf1/cip1 with PCNA. Oncogene 11:1931-1937.
8. Crooke ST (1997) Progress in antisense therapeutics discovery and development. Ciba Found Symp 209:158-164.
9. Desjardins JP and Iversen PL (1995) Inhibition of rat cytochrome P450 3A2 by an antisense oligonucleotide in vivo. J Pharmacol Exp Ther 275:1608-1613.
10. El-Deiry WS (1998) p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol 227:121-137.
11. Esterbauer H and Cheeseman KH (1990) Determination of aldehyde lipid peroxidation products: Malondehyde and 4-hydroxynoneal. Methods Enzymol 186:407-421.
12. Foley J, Ton T, Maronpot R, Butterworth B and Goldsworthy TL (1993) Comparison of proliferating cell nuclear antigen to tritiated thymidine as a marker of proliferating hepatocytes in rats. Environ Health Perspect 101 (Suppl 5):199-206.
13. Fraker PJ, King LE, Lill-Elghanian D and Telford WG (1995) Quantification of apoptotic events in pure and heterogeneous populations of cells using the flow cytometer. Methods Cell Biol 46:57-76.
14. Franklin M and Estabrook R (1971) On the inhibitory action of mersalyl on microsomal drug oxidation: A rigid organization of the electron transport chain. Arch Biochem Biophys 143:318-329.
15. Giles RV, Spiller DG, Clark RE and Tidd DM (1999) Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev 9:213-220.
16. Hainaut P and Milner J (1993) Redox modulation of p53 confirmation and sequence specific DNA binding in vitro. Cancer Res 53:4469-4473.
17. Higgins GM and Anderson RM (1931) Restoration of liver following partial surgical removal. Arch Pathol 12:186.
18. Iversen PL, Mata JE, Tracewell W and Zon G (1994) Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human HIV type 1 in adult male rat following single injections and continuous infusions. Antisense Res Dev 4:43-52.
19. Koop D (1986) Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P450 isozyme 3A. Mol Pharmacol 29:399-404.
20. Kren BT, Trembley JH and Steer CJ (1996) Alterations in mRNA stability during rat liver regeneration. Am J Physiol 270:G763-G777.
21. Lambotte L, Saliez A, Triest S, Tagliaferri EM, Barker AP and Barans AG (1997) Control of rate and extent of the proliferate response after partial hepatectomy. Am J Physiol 273:G905-G912.
22. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
23. Lu X and Lane DP (1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes. Cell 75:765-778.
24. Magnelli L, Ruggiero M and Chiarugi V (1992) The old and the new in p53 functional regulation. Biochem Mil Med 62:3-10.
25. Michalopoulos GK and DeFrances MC (1996) Liver regeneration. Science (Wash DC) 276:60-66.
26. Milner J (1995) DNA damage, p53 and anticancer drugs. Nat Med 1:879-880.
27. Monia BP, Sasmor H, Johnston JF, Freir SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H and Fabbro D (1996) Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 93:15481-15484.
28. Morin O and Normand C (1986) Long-term maintenance of hepatocyte cultures. J Cell Physiol 129:103.
29. Nash T (1953) The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 55:416-421.
30. Neckers LM and Iyer K (1997) Non-antisense effects of antisense oligonucleotides, in Antisense Oligodeoxynucleotides and Antisense RNA (Weiss B ed) pp 57-78, CRC Press, Boca Raton, FL.
31. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T and Yasumoto K (1997) Cytochrome P4502E1 polymorphism as a risk factor for lung cancer: In relation to p53 gene mutation. Anticancer Res 17:583-587.
32. 32P-analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic, mitomycin C. Mutat Res 179:75-88.
33. Shimoji M, Itoh S, Toide K, Nakayama K, Aizawa S and Kamataki T (1996) Application of primary hepatocytes from p53-knockout mice for studies of expression of CYP3A. J Biochem 120:42-48.
34. Summerton J, Stein D, Huang SB, Matthews P, Weller D and Partridge M (1997) Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 7:63-70.
35. Sunderman FW Jr, Marzouk A, Hopfer SM, Zaharia O and Reid MC (1985) Increased lipid peroxidation in tissues of nickel chloride treated rats. Ann Clin Lab Sci 15:229-236.
36. Wagner RW, Matleucci MD, Grant D, Huang T and Froehler BC (1996) Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotechnol 14:840-844.
37. Waldman T, Lengauer C, Kinzler KW and Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond) 381:713-716.
38. Wrighton SA, Schuetz EG, Watkins PB, Maurel P, Barwick J, Bailey BS, Hartle HT, Young B and Guzelian PS (1985) Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. Mol Pharmacol 28:312-321.
39. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF and Chen CJ (1999) A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29:697-702.